Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AC2307 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| 5 | PLACEBO_COMPARATOR | - |
| 6 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AC2307 | DRUG | subcutaneous, twice daily, low dose |
| placebo | DRUG | subcutaneous, twice daily, low dose |
Inclusion Criteria: \- Is obese with a body mass index (BMI) ≥30 kg/m\^2 to ≤45 kg/m\^2, or is overweight with a BMI ≥27 kg/m\^2 to \<30 kg/m\^2 and has at least one weight-related comorbidity (dyslipidemia, impaired fasting glucose, hypertension, obstructive sleep apnea syndrome, polycystic ovary ...
Top 20 of 32 competitors
AC2307 is an investigational small molecule being developed for the treatment of obesity and overweight. It is administered subcutaneously and is currently in Phase 2 clinical development. The drug is being studied for its effect on body weight in obese or overweight subjects.
AC2307 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of AC2307 in patients with obesity or overweight.
AC2307 is in Phase 2 clinical development. A Phase 2 trial has been completed, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not yet been approved by regulatory authorities.
AC2307 has been studied in one clinical trial with the identifier NCT00785408. This Phase 2 study examined the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects. The trial enrolled 273 participants in the United States and has been completed.
The AC2307 clinical trial, NCT00785408, was a randomized, double-blind, placebo-controlled study. It enrolled 273 participants aged 18 years and older, including both males and females, with obesity or overweight. The trial was conducted in the United States and has been completed.